Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials.|
|Authors: ||Liberman, U.|
|Issue Date: ||2006|
|Citation: ||INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 60(11). p. 1394-1400|
|Abstract: ||A number of antiresorptive agents reduce the risk of vertebral fractures, but few have shown consistent effects on hip and other non-spine fractures. Meta-analysis provides a more precise estimate than individual trials when results are consistent across pooled trials. Earlier meta-analyses summarised the results for vertebral and non-spine fractures. New data have emerged for hormone therapy (HT), alendronate (ALN), risedronate (RIS) and ibandronate (IBN). We surveyed recent reports of randomised, placebo-controlled trials with non-spine and/or hip fracture data, and used meta-analysis where appropriate to test for heterogeneity and derive pooled estimates. The magnitude of effect on hip fracture appears to be similar to that for non-spine fracture for each drug, but differs among drugs. Based on the current data, ALN reduces the risk of hip and non-spine fracture by 49–55%, HT by 25–36% and RIS by 26–27%. There is insufficient and/or inconsistent evidence of an effect on these fractures for IBN, calcitonin and raloxifene.|
|ISI #: ||000241190700012|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2007|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.